CCL2 and neoplasm: By day 37, in the NGP-Fluc mice, combination therapy demonstrated a significant decrease in tumor burden compared to the PBS control group (p < 0.01) and the anti-CCL2 antibody alone group (p < 0.01), but not compared to the etoposide alone group (Fig. 6C,D).